X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Through the acquisition, Immunome have the access for AL102, a small molecule gamma secretase inhibitor currently being evaluated for the treatment of desmoid tumors, and related drug candidate AL101 from Ayala.
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Immunome
Deal Size: $87.5 million Upfront Cash: $20.0 million
Deal Type: Acquisition March 26, 2024
Details:
AL102 is an inhibitor of gamma secretase-mediated notch signaling. It is being evaluated in phase 3 clinical trials for the treatment of desmoid tumors.
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Bristol Myers Squibb
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 20, 2024
Details:
Through the acquisition, Immunome will have the access for AL102, a small molecule gamma secretase inhibitor currently being evaluated for the treatment of desmoid tumors, and related drug candidate AL101 from Ayala.
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Immunome
Deal Size: $87.5 million Upfront Cash: $20.0 million
Deal Type: Acquisition February 06, 2024
Details:
AL102 is an investigational small molecule, which is act as Gamma Secretase Inhibitor, which is investigated for the treatment of Desmoid Tumors and received orphan drug designation from FDA.
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 06, 2023
Details:
The combined company will work to advance a portfolio of oncology assets, with a primary focus on Ayala’s AL102, a once-daily, potent, selective, oral gamma-secretase inhibitor (GSI) and Biosight’s Aspacytarabine (BST-236).
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Biosight
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger October 19, 2023
Details:
The combined company will work to advance a portfolio of oncology assets, with a primary focus on Ayala’s AL102, a once-daily, potent, selective, oral gamma-secretase inhibitor (GSI) and Biosight’s Aspacytarabine (BST-236).
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Recipient: Biosight
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger July 27, 2023
Details:
AL102 is an investigational small molecule gamma secretase inhibitor (GSI) that is designed to potently and selectively inhibit Notch 1, 2, 3 and 4, and is currently being evaluated in the Phase 2/3 RINGSIDE clinical studies in patients with progressing desmoid tumors.
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 05, 2023
Details:
AL102 for the treatment of desmoid tumors, which are rare, debilitating, and often disfiguring types of soft tissue tumors. AL102 is currently being studied in our Phase 2/3 RINGSIDE trial for the treatment of patients with progressing desmoid tumors.
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 03, 2023
Details:
The merged company will be focused primarily on the development and commercialization of Ayala’s lead program AL102 for the treatment of desmoid tumors.
Lead Product(s): AL102
Therapeutic Area: Oncology Product Name: AL102
Highest Development Status: Phase II/ Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Ayala Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Merger January 19, 2023
Details:
ADXS-504 is a novel Lm-based immunotherapy designed to express multiple tumor antigen targets, potentially leading to generation of a broad set of effector T cells and NK cells that may enhance tumor control.
Lead Product(s): ADXS-504
Therapeutic Area: Oncology Product Name: ADXS-504
Highest Development Status: Phase IProduct Type: Vaccine
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
